Additionally, silencing of NFKB1 or NPTX1 resulted in restoring the pro-angiogenic and aggressive features of the glioma cells, which had been inhibited by SLC26A4-AS1 expression. The gene discussed is SLC26A4; the disease is central nervous system cancer.